Market Spotlight: Hereditary Angioedema
Market Spotlight: Hereditary Angioedema
$1,318.00
This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Meddevicetracker
- Description
- Contents
Overview
This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2019, using the most commonly cited prevalence estimate of 1:50,000, there were approximately 154,300 prevalent cases of hereditary angioedema (HAE) worldwide, and forecasts that number to increase to approximately 168,100 prevalent cases by 2028.
- The approved drugs in the HAE space target complement pathway, androgen receptors, follicle-stimulating hormone, gonadotropin-releasing hormone, progesterone receptor, bradykinin B2 receptor, and the kinin-kallikrein system. These are commonly administered via the intravenous, subcutaneous, and oral routes.
- Industry-sponsored drugs in active clinical development for HAE are spread evenly across Phase I and Phase II. Therapies in development for HAE focus on targets such as the kinin-kallikrein system, coagulation factor XII, and bradykinin B2 receptor. The majority of pipeline drugs are administered via the oral route, with the remainder being tested as subcutaneous formulations.
- High-impact upcoming events for drugs in the HAE space comprise topline Phase II trial results for IONIS PKK-LR, topline Phase III trial results for Orladeyo, topline Phase Ib/II trial results for QLS-215, and a data exclusivity expiration for Ruconest.
- The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 19%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.2 years in the overall autoimmune/immunology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for HAE have been in the early and midphases of development, with 53% of trials in Phase I–II, and 47% in Phase III–IV.
- The US has the highest number of HAE clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.
- Clinical trial activity in the HAE space is dominated by completed trials. Takeda has the highest number of completed clinical trials for HAE, with 37 trials.
- Takeda leads industry sponsors with the highest overall number of clinical trials for HAE, followed by BioCryst.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 C1-INH concentrates
9 Plasma-derived C1-INH (pdC1-INH)
9 Recombinant C1-INH (rhC1-INH)
9 Kallikrein inhibitors
10 Bradykinin receptor antagonist
11 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 KVD900 for HAE (February 9, 2021)
23 Garadacimab for HAE (June 8, 2020)
25 Orladeyo for HAE (January 12, 2020)
26 Orladeyo for HAE (November 6, 2019)
29 KEY UPCOMING EVENTS
30 KEY REGULATORY EVENTS
30 CHMP Recommends BioCryst’s Orladeyo For EU-Wide Approval
30 Orladeyo Receives Approval For HAE In Japan
30 Takeda’s Takhzyro Gets Nod In China
30 BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
31 UK Early Access For BioCryst’s Hereditary Angioedema Drug
31 Adalvo Files For Generic Version Of Takeda’s Firazyr
31 BioCryst Pharmaceuticals’ berotralstat Among 14 New Hopefuls At EMA
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 Catabasis Acquires Quellis And Its HAE Candidate
34 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
40 BIBLIOGRAPHY
41 Prescription information
42 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of HAE, 2019–28
18 Figure 2: Overview of pipeline drugs for HAE in the US
18 Figure 3: Pipeline drugs for HAE, by company
19 Figure 4: Pipeline drugs for HAE, by drug type
19 Figure 5: Pipeline drugs for HAE, by classification
23 Figure 6: KVD900 for HAE (February 9, 2021): Phase II – On-Demand Treatment
25 Figure 7: Garadacimab for HAE (June 8, 2020): Phase II – CSL312_2001
26 Figure 8: Orladeyo for HAE (January 12, 2020): Phase III – APeX-J (Japan)
28 Figure 9: Orladeyo for HAE (November 6, 2019): Phase II/III – APeX-S, Phase III – APeX-2
29 Figure 10: Key upcoming events in HAE
32 Figure 11: Probability of success in the autoimmune/immunology-other pipeline
36 Figure 12: Clinical trials in HAE
36 Figure 13: Top 10 drugs for clinical trials in HAE
37 Figure 14: Top 10 companies for clinical trials in HAE
37 Figure 15: Trial locations in HAE
38 Figure 16: HAE trials status
39 Figure 17: HAE trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of HAE, 2019–28
16 Table 2: Marketed drugs for HAE
20 Table 3: Pipeline drugs for HAE in the US
22 Table 4: KVD900 for HAE (February 9, 2021)
24 Table 5: Garadacimab for HAE (June 8, 2020)
25 Table 6: Orladeyo for HAE (January 12, 2020)
27 Table 7: Orladeyo for HAE (November 6, 2019)
34 Table 8: Historical global sales, by drug ($m), 2015–19
35 Table 9: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Arthroscopy Products and Sports Medicine Fixation Implants (2021) 
Sign up to the